Network Pharmacology and Experimental Validation Reveal Aidi Injection Suppresses Prostate Cancer via EGFR Inhibition and STAT3-Mediated Apoptosis Authors: Ganhua You, Chen Qian, Xiaoyue Chen, Qunying An, Jukun Song, Yuehai Xiao Published: 2025 ABSTRACT BackgroundProstate cancer (PCa) is the most common male reproductive malignancy, with traditional Chinese medicine (TCM) offering potential complementary treatments. Aidi injection, used for liver, lung, and colorectal cancers, shows promise for PCa, but its mechanisms are unclear. This study aims to uncover the molecular pathways through which Aidi injection affects PCa using network pharmacology and experiments.MethodsThe study used network pharmacology to identify active components of Aidi injection and their targets from various databases. These targets were cross-referenced with PCa-related targets to uncover therapeutic possibilities. Protein-protein interaction (PPI) and KEGG pathway analyses highlighted key molecular pathways affected by Aidi injection. Molecular docking examined ingredient-target binding. In vitro tests evaluated effects on PCa cell proliferation, apoptosis, and IL-6/STAT3 signaling, while in vivo studies assessed tumor growth and immune response in mice.ResultsThe study identified 58 active components and 804 PCa-related target genes, with 49 overlapping therapeutic targets. Key compounds such as quercetin, kaempferol, isorhamnetin, and cantharidin were highlighted. Core targets included ESR1, IL-6, STAT3, HSP90AA1, EGFR, and VEGFA. KEGG analysis revealed the IL-6/STAT3 and EGFR pathways as significant in PCa treatment. In vitro, Aidi injection inhibited PCa cell proliferation, induced apoptosis, and suppressed IL-6/STAT3 activation. In vivo, Aidi injection reduced tumor growth and enhanced immune response in mice.ConclusionsAidi injection influences the IL-6/STAT3 and EGFR pathways, suppressing PCa cell growth, inducing apoptosis, and reducing migration and invasion. These findings offer valuable insights into the therapeutic potential of Aidi injection for prostate cancer.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12575-025-00299-w. Introduction Prostate cancer is among the most prevalent malignant tumors in men, with a steadily rising incidence each year, posing a serious public health concern. Although various treatments are available, challenges such as drug resistance and side effects persist [1]. This highlights the need for more effective therapies that enhance patient outcomes and improve quality of life. Traditional Chinese Medicine (TCM) offers several advantages in managing cancer, including inhibiting tumor growth, minimizing side effects, delaying recurrence and metastasis, alleviating symptoms, improving quality of life, and extending survival [2]. In China, TCM has become an increasingly vital component in prostate cancer treatment. Aidi Injection is a multi-component, well-defined compound formulation made from various traditional Chinese medicine ingredients. Its formula has been clinically applied for many years, and its composition and efficacy have been thoroughly documented in existing literature. Therefore, further separation or identification of its components is unnecessary. As a multi-targeted anti-tumor drug, Aidi injection has garnered significant attention for its ability to inhibit cancer cell proliferation and promote apoptosis [3, 4]. Unlike many traditional anti-cancer medications, Aidi injection supports the immune system by avoiding bone marrow suppression and increasing white blood cell counts. It is widely used to treat various cancers, including lung, gastric, breast, and prostate cancers [5]. When combined with the chemotherapy agent cisplatin, Aidi injection significantly enhances treatment effectiveness, raising the clinical response rate from 38.39 to 68.57%, while also reducing side effects like anorexia and vomiting from 54.55 to 28.57% [6]. The primary components of Aidi injection include Mylabris phalerata (animal drug), Astmgali Radix (Astragalus mongholicus Bunge), Ginseng Radix Et Rhizoma (Panax ginseng C. A. Mey.) and Acanthopanacis Senticosi Radix Et Rhizoma Seu Caulis (Eleutherococcus senticosus (Rupr. & Maxim.) Maxim), among others. All plant name corresponds to the latest revision in World Flora Online (www.worldfloraonline.org). Table 1 details the specific composition and preparation method. Mylabris phalerata, a core ingredient with recognized anti-cancer properties, contains cantharidin, known for its anti-cancer, immune-boosting, antiviral, and antioxidant benefits [7]. Panax ginseng and Astragalus mongholicus, renowned for their strengthening properties, are beneficial for stabilizing health, enhancing quality of life, and prolonging survival among cancer patients [8, 9]. Often called the “King of Herbs” in China, Panax ginseng is traditionally valued for its ability to support organ health, calm the mind, expel harmful agents, and promote longevity. These effects contribute significantly to strengthening adaptability, enhancing immunity, and supporting overall well-being, making them crucial components in cancer care. Table 1The composition and dosage of Aidi injectionLatin nameChinese nameMedicinal partWeight (g)World flora onlineAstragalus mongholicus BungeHuangqiRoot100wfo-0000452676Eleutherococcus senticosus (Rupr. & Maxim.) MaximCiwujiaRoot/Rhizoma150wfo-0000452676Panax ginseng C. A. Mey.RenshenRoot50wfo-0000452676 Mylabris phalerata BanmaoInsect body (animal drug)1.5NonePreparation methodThe production process of Aidi injection involves precise extraction, purification, and formulation steps, with strict control over specific parameters. First, ginseng is extracted using 30%−80% ethanol, followed by reflux extraction at 65℃−85℃ for two sessions, with the first lasting 2.5–4 h and the second 1–2 h. The extract is filtered, ethanol is recovered, and the solution is concentrated for later use. Astragalus and Eleutherococcus, combined with the ginseng residue, are decocted 2–4 times, each session lasting 2.5–4 h. The resulting extract is filtered, concentrated, and combined with the ginseng extract. The combined solution undergoes ethanol precipitation at a 70%−80% ethanol concentration, is cold-stored for 24 h, filtered, and subjected to multiple rounds of water precipitation and ultrafiltration. The pH is adjusted to 7.0−7.6, and the solution is stored at 4℃ for further use. Mylabris is soaked in water, then decocted at 90℃−100℃ for 0.5–2 h, filtered, and concentrated. The concentrated solution is adjusted to a 70%−90% ethanol concentration for ethanol precipitation, cold-stored for 12–24 h, and filtered. Multiple rounds of water precipitation and pH adjustment to 4.0–5.0 follow, alongside cold storage and ultrafiltration, yielding a purified Mylabris extract. Subsequently, the purified extracts are mixed at specified proportions, with 3%−10% glycerol and 0.05%−0.1% polysorbate−80 added as excipients. The solution is diluted to the desired concentration, with its pH adjusted to 7.0−7.5, and terminal filtration is conducted to remove particulates. Finally, the solution undergoes sterilization at 121℃ for 15–30 min and is aseptically filled into ampoules or vials. Throughout the process, strict control of temperature, time, and solvent concentration ensures the purity, efficacy, and safety of the final product.Quality control reported?(Y/N)Y-National Pharmaceutical Standard Z52020236; Standard number: WS3-B−3809−98 Table 1The composition and dosage of Aidi injectionLatin nameChinese nameMedicinal partWeight (g)World flora onlineAstragalus mongholicus BungeHuangqiRoot100wfo-0000452676Eleutherococcus senticosus (Rupr. & Maxim.) MaximCiwujiaRoot/Rhizoma150wfo-0000452676Panax ginseng C. A. Mey.RenshenRoot50wfo-0000452676 Mylabris phalerata BanmaoInsect body (animal drug)1.5NonePreparation methodThe production process of Aidi injection involves precise extraction, purification, and formulation steps, with strict control over specific parameters. First, ginseng is extracted using 30%−80% ethanol, followed by reflux extraction at 65℃−85℃ for two sessions, with the first lasting 2.5–4 h and the second 1–2 h. The extract is filtered, ethanol is recovered, and the solution is concentrated for later use. Astragalus and Eleutherococcus, combined with the ginseng residue, are decocted 2–4 times, each session lasting 2.5–4 h. The resulting extract is filtered, concentrated, and combined with the ginseng extract. The combined solution undergoes ethanol precipitation at a 70%−80% ethanol concentration, is cold-stored for 24 h, filtered, and subjected to multiple rounds of water precipitation and ultrafiltration. The pH is adjusted to 7.0−7.6, and the solution is stored at 4℃ for further use. Mylabris is soaked in water, then decocted at 90℃−100℃ for 0.5–2 h, filtered, and concentrated. The concentrated solution is adjusted to a 70%−90% ethanol concentration for ethanol precipitation, cold-stored for 12–24 h, and filtered. Multiple rounds of water precipitation and pH adjustment to 4.0–5.0 follow, alongside cold storage and ultrafiltration, yielding a purified Mylabris extract. Subsequently, the purified extracts are mixed at specified proportions, with 3%−10% glycerol and 0.05%−0.1% polysorbate−80 added as excipients. The solution is diluted to the desired concentration, with its pH adjusted to 7.0−7.5, and terminal filtration is conducted to remove particulates. Finally, the solution undergoes sterilization at 121℃ for 15–30 min and is aseptically filled into ampoules or vials. Throughout the process, strict control of temperature, time, and solvent concentration ensures the purity, efficacy, and safety of the final product.Quality control reported?(Y/N)Y-National Pharmaceutical Standard Z52020236; Standard number: WS3-B−3809−98 The composition and dosage of Aidi injection Quality control reported? (Y/N) Research and application of Aidi injection in lung cancer have an extensive history. In cases of non-small cell lung cancer, numerous clinical studies indicate that Aidi injection, when used alongside chemotherapy, can significantly alleviate patient symptoms, reduce tumor size, minimize chemotherapy-related side effects, and improve quality of life. Clinical reports also suggest it may enhance prostate cancer treatment outcomes, though the precise therapeutic mechanisms remain unknown [10]. Network pharmacology offers a pathway to uncover Aidi injection’s mechanisms of action, identify new drug targets, and predict possible therapeutic effects. This study seeks to investigate Aidi injection’s mechanisms in treating prostate cancer through network pharmacology, aiming to provide a scientific foundation for its clinical use. Materials and Methods Network Pharmacology-Base Analysis Identification and Screening of Active Components in Aidi Injection To identify the active components of Aidi injection, we used the TCMSP platform (http://tcmspw.com/tcmsp.php) and TCM-ID database (https://bidd.group/TCMID/index.html) to screen for ingredients based on specific criteria. Oral bioavailability (OB) indicates the percentage of unchanged drug reaching systemic circulation, and drug-likeness (DL) reflects structural similarity to known drugs. Specifically, we now indicate that OB ≥ 30% and DL ≥ 0.18 were used as the thresholds for compound selection, based on commonly accepted standards in network pharmacology research [11]. The TCM-ID database identified the active compound of Eleutherococcus senticosus as a viable candidate. Identify Target Genes of Active Ingredients To gather data on the active ingredients, we first searched the TCMSP database and documented their identifiers. This information was then cross-checked with the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) to retrieve the corresponding SMILES numbers. Target information for these ingredients was predicted using both the DrugBank (http://www.drugbank.ca) and SwissTargetPrediction (http://swisstargetprediction.ch/) databases. Finally, we normalized the target data by using UniProt’s standardized protein identifiers and annotations (http://www.UniProt.org/). Screening of Potential Targets for Prostate Cancer To identify key genes associated with prostate cancer, we queried three online databases: DisGeNET (https://www.disgenet.org/), GenCLiP 3 (http://cismu.net/genclip3/analysis.php) and GeneCards (https://www.genecards.org/). DisGeNET provides gene-disease associations, GenCLiP 3 analyzes gene-disease relationships based on gene expression data, and GeneCards offers comprehensive gene information. We selected genes that were identified as related to prostate cancer across all three databases, and the overlapping targets were considered as the primary candidates for prostate cancer treatment. Construction of the Drug-Active Compound-Therapeutic Target Network To visualize the relationships between genes associated with Aidi injection components and those linked to prostate cancer, a Venn diagram was constructed. This diagram facilitated the identification of common genes shared between the components of Aidi injection and prostate cancer targets. After removing duplicate genes, a more refined drug-active compound-target network was built using Cytoscape 3.7.1 software. Cytoscape is widely used for visualizing molecular interaction networks and integrating these networks with various types of data. In this network, nodes represent key elements, including traditional Chinese herbal medicines, their active compounds, and the therapeutic targets related to prostate cancer. The edges between the nodes indicate the interactions or relationships between these components-connecting drugs with their active ingredients and those ingredients with the therapeutic targets. The number of edges between nodes reflects the degree of connectivity, providing insight into the strength and significance of the interactions. By analyzing this network, we were able to identify potential key compounds and their related molecular pathways, offering a clearer understanding of the therapeutic mechanisms of Aidi injection in prostate cancer treatment. Construction and Analysis of Protein-Protein Interaction Network To better understand interactions among target genes, we uploaded the selected genes to the STRING database (http://string-db.org) to acquire protein-protein interaction (PPI) data. Cytoscape 3.7.1 software was then used to visualize the PPI network, with node size and color indicating hub genes. Screening and Verification of Differentially Expressed Genes Using the keywords “prostate cancer; prostate carcinoma; prostatic cancer,” we searched for gene chip datasets in the GEO database. The screening criteria required: (1) mRNA genomic chip datasets, (2) inclusion of both cancerous and adjacent tissues, and (3) a sample size of more than 20. From the results, we selected GSE46602, which includes 36 cancer samples and 14 adjacent tissue samples. For analysis of the GSE46602 dataset, we used the GEO2R online tool (https://www.ncbi.nlm.nih.gov/geo/geo2r/) and applied a threshold of |log2 (fold change)| >0.5 and p-adjust < 0.05 to identify differentially expressed genes. These genes were then cross-referenced with previously identified therapeutic targets to determine hub genes for Aidi injection’s potential in treating prostate cancer in vivo. GO Function and KEGG Pathway Enrichment Analysis To comprehensively explore the biological effects of Aidi injection in prostate cancer treatment, we conducted Gene Ontology (GO) functional and pathway enrichment analyses. The GO analysis, performed using the STRING database, was categorized into three major aspects: biological process (BP), molecular function (MF), and cellular component (CC). This allowed us to identify specific biological processes, molecular activities, and cellular locations that may be impacted by Aidi injection’s active components in prostate cancer treatment. By examining the associated genes in these categories, we were able to gain insights into the molecular mechanisms and potential therapeutic effects of Aidi injection. In addition to GO analysis, we further explored the enriched pathways linked to the hub target genes using the Reactome database (http://reactome.ncpsb.org/). Reactome offers a robust framework for understanding pathway relationships, providing detailed information on how various biological pathways are interconnected. It also emphasizes parent-child connections within pathways, helping to reveal complex functional processes and regulatory networks. This comprehensive pathway enrichment analysis enabled us to uncover key signaling pathways potentially influenced by Aidi injection, which could contribute to its therapeutic efficacy in prostate cancer treatment. Molecular Docking Analysis To evaluate binding affinities and interaction modes between drug candidates and their targets, we used AutodockVina 1.2.2, a protein-ligand docking tool. Molecular structures of selected compounds were sourced from PubChem Compound (https://pubchem.ncbi.nlm.nih.gov/). The 3D coordinates for IL-6 (PDB ID: 1alu), STAT3 (PDB ID: 6NUQ), EGFR (PDB ID: 8A27), ESR1 (PDB ID: 7KBS), and HSPAA1 (PDB ID: 3O01) were acquired from the Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/home.do). Molecular docking simulations were performed using Autodock Vina 1.5.7 to assess the binding affinities of small molecules with STAT3 (PDB ID: 6NUQ) and EGFR (PDB ID: 8A27). The active sites for both proteins were selected based on structural analysis and literature. The detailed information is as follows: (1). STAT3 (PDB ID: 6NUQ) The key binding site for STAT3 is the SH2 domain, specifically around Tyr-705, a critical phosphorylation site involved in dimerization. This site was chosen for docking simulations to evaluate the small molecules’ interaction with STAT3’s activation mechanism. (2). EGFR (PDB ID: 8A27) For EGFR, the active site is located in the ATP-binding pocket within the kinase domain. Key residues involved in ATP binding, including Glu-762, Lys-745, Asp-813, and Glu-837, were selected for docking to assess the inhibitory potential of small molecules. (3). Docking Procedure Protein structures were prepared by removing water molecules and adding hydrogens. Ligand structures were obtained from PubChem and converted to PDBQT format. Docking was performed with grid boxes centered on Tyr-705 for STAT3 and the ATP-binding pocket for EGFR, with a grid spacing of 0.375 nm. Binding energy values were calculated, and key interactions were analyzed to evaluate the compounds’ affinity and potential inhibition of STAT3 and EGFR. Experimental Validation Cell Lines, Culture Conditions, and Reagents RM-1, DU145, and BPH-1 cell lines were obtained from the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM, HyClone) with 10% fetal bovine serum (FBS, HyClone) at 37℃ in a humidified incubator with 95% air and 5% CO2. The treatments included the following compounds: Quercetin (Selleck, S2391), Kaempferol (MedChemExpress, HY-14590), Isorhamnetin (MedChemExpress, HY-N0776), and Cantharidin (MedChemExpress, HY-N0209), sourced from Selleck and MCE. Each was dissolved in dimethyl sulfoxide (DMSO) at 100 mmol/L and stored at −20℃. The CCK-8 and DAPI kits were from Solarbio Life Sciences (Beijing, China), while the IP-10 (CXCL10) Mouse ELISA Kit and IL-6 Mouse Uncoated ELISA Kit were acquired from Invitrogen (Hong Kong, China). Aidi injection was obtained from Guizhou Yibai Pharmaceutical Co., Ltd. (Guizhou, China), approval number: Z52020236. Prior to use, the injection was diluted to the required concentration using DMEM medium, followed by the addition of 10% FBS, and then used for cellular assays. Antibodies of Bcl-xl (catalogue, #2764S), PCNA (catalogue, #13110S), Bax (catalogue, #2772S), BIRC5(catalogue, #2808S), β-actin (catalogue, #4967S) and P-STAT3 (Thy705) (catalogue, #9145s) were purchased from the Cell Signaling Technology (CST) company. Antibodies of IL-6 (catalogue, #A0286), STAT3(catalogue, #A16975), AKT1/2(catalogue, #A2696) and P-AKT1 (Ser479) (catalogue, #AP0637) were purchased from the Abclonal technology (Wuhan, China). The second antibody chemiluminescence (ECL, Thermo Fisher Scientific) was used to captured antibody conjugates. CCK-8 and Clonogenic Survival Assay RM-1, DU145, and BPH-1 cells were plated in 96-well plates at a density of 1 × 10⁴ cells per well and treated with varying concentrations of Aidi injection (0, 6.25, 12.5, 25, 50, 100, 200 mg/mL) for 24 and 48 h. After treatment, 10 µL of CCK-8 solution was added to each well, and absorbance was measured at 450 nm using a Vario Skan Flash microplate reader (Thermo Scientific, USA) [12]. Finally, we input the obtained concentrations and cell viability data into GraphPad Prism software to perform nonlinear regression analysis, from which the IC50 value was calculated. For clonogenic assays, RM-1 and DU145 cells were seeded in plates at a density of 3 × 10⁵ cells per plate and treated with different concentrations of Aidi injection (0, 25, 50, 100 mg/mL) for 24 h. Following treatment, the cells were re-plated at 1000 cells per plate and incubated for 14 days. Afterward, the cells were fixed in 4% paraformaldehyde for 15 min and stained with 0.1% crystal violet for 10 min. Wound Healing Assay To evaluate cell migration ability, a wound healing assay was performed. First, cells were seeded in 6-well plates and cultured to confluence. A sterile 10 µL pipette tip was used to create a linear scratch in the center of each well. The wells were then washed with PBS to remove floating cells. Fresh medium containing 10% FBS and appropriate treatments (Aidi injection-treated group and control group) was added, and the cells were cultured at 37℃in a 5% CO2 incubator. At different time points, images of the scratch area were captured using a phase-contrast microscope. The remaining wound area was measured to calculate the wound closure rate and assess the effects of treatments on cell migration. DAPI Staining and Flow Cytometry Assay Cells were plated in six-well plates at an initial density of 3 × 10⁵ cells per well and treated with various concentrations of Aidi injection for 24 h. Following treatment, cells were stained with DAPI (Beyotime, Jiangsu, China) as per kit instructions, and stained nuclei were visualized under a fluorescence microscope (Nikon Corporation, Japan). For apoptosis analysis, cells were stained with annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) using the BD Pharmingen kit (USA). Cells were grown to 70% confluency and treated with Aidi injection at 0, 25, 50, and 100 mg/mL for 24 h. After treatment, cells were trypsinized, rinsed twice with cold PBS, and resuspended in 500 µL binding buffer in microcentrifuge tubes, followed by 5 µL each of FITC and PI staining. Apoptosis was then analyzed using a flow cytometer (Becton Dickinson, Franklin Lakes, USA). JC-1 Staining Assay To assess mitochondrial membrane potential, cells were seeded in 6-well plates and treated with Aidi injection at concentrations of 25 mg/mL and 50 mg/mL. After 24 h of treatment, cells were washed with PBS and incubated with JC-1 dye (5 µg/mL) in serum-free medium for 30 min at 37 °C in the dark. After incubation, cells were washed again with PBS and analyzed using fluorescence microscopy. Red fluorescence (590 nm emission) indicates high mitochondrial membrane potential, while green fluorescence (535 nm emission) indicates a loss of membrane potential. The red/green fluorescence ratio was calculated to evaluate mitochondrial function. Q-RT-PCR and Western Blot RM-1 and DU145 cells were seeded in six-well plates and treated with Aidi injection for 12 h. qRT-PCR was conducted on a StepOne Plus thermal cycler (Applied Biosystems, Forest City, CA, USA) using specific primers and FastStart Universal SYBR Green Select Master Mix as previously detailed [13]. The genes to be tested in these two cell lines include: Vimentin, E-cadherin, TGF-β, IL6, CXCL-10, IFNγ, and PDL-1. β-actin served as the reference gene, and primers are listed in Table 2. Table 2DNA oligonucleotides and quantitative PCR primer sequenceQuantitative PCR primer sequences for miceQuantitative PCR primer sequences for humanβ-actinForwardCCGTTGACATCCGTAAAGACCβ-actinForwardCTCCATCCTGGCCTCGCTGTReversedAACAGTCCGCCTAGAAGCACReversedGCTGTCACCTTCACCGTTCCIL-6ForwardTAGTCCTTCCTACCCCAATTTCCIL-6ForwardACTCACCTCTTCAGAACGAATTGReversedTTGGTCCTTAGCCACTCCTTCReversedCCATCTTTGGAAGGTTCAGGTTGCXCL-10ForwardCCAAGTGCTGCCGTCATTTTCCXCL-10ForwardTGGCATTCAAGGAGTACCTCReversedGGCTCGCAGGGATGATTTCAAReversedTTGTAGCAATGATCTCAACACGIFN-γForwardGCCACGGCACAGTCATTGAIFN-γForwardTCGGTAACTGACTTGAATGTCCAReversedTGCTGATGGCCTGATTGTCTTReversedTCGCTTCCCTGTTTTAGCTGCPDL-1ForwardGCTCCAAAGGACTTGTACGTGPDL-1ForwardTGGCATTTGCTGAACGCATTTReversedGCTCCAAAGGACTTGTACGTGReversedTGCAGCCAGGTCTAATTGTTTTE-cadherinForwardGGTCATCAGTGTGCTCACCTCTE-cadherinForwardGCCTCCTGAAAAGAGAGTGGAAGReversedGCTGTTGTGCTCAAGCCTTCACReversedTGGCAGTGTCTCTCCAAATCCGVimentinForwardCGGAAAGTGGAATCCTTGCAGGVimentinForwardAGGCAAAGCAGGAGTCCACTGAReversedAGCAGTGAGGTCAGGCTTGGAAReversedATCTGGCGTTCCAGGGACTCATTGF-βForwardTGATACGCCTGAGTGGCTGTCTTGF-βForwardGAGCTCCGAGAAGCGGTACCTReversedCACAAGAGCAGTGAGCGCTGAAReversedAGGCTCCAAATGTAGGGGCAGG Table 2DNA oligonucleotides and quantitative PCR primer sequenceQuantitative PCR primer sequences for miceQuantitative PCR primer sequences for humanβ-actinForwardCCGTTGACATCCGTAAAGACCβ-actinForwardCTCCATCCTGGCCTCGCTGTReversedAACAGTCCGCCTAGAAGCACReversedGCTGTCACCTTCACCGTTCCIL-6ForwardTAGTCCTTCCTACCCCAATTTCCIL-6ForwardACTCACCTCTTCAGAACGAATTGReversedTTGGTCCTTAGCCACTCCTTCReversedCCATCTTTGGAAGGTTCAGGTTGCXCL-10ForwardCCAAGTGCTGCCGTCATTTTCCXCL-10ForwardTGGCATTCAAGGAGTACCTCReversedGGCTCGCAGGGATGATTTCAAReversedTTGTAGCAATGATCTCAACACGIFN-γForwardGCCACGGCACAGTCATTGAIFN-γForwardTCGGTAACTGACTTGAATGTCCAReversedTGCTGATGGCCTGATTGTCTTReversedTCGCTTCCCTGTTTTAGCTGCPDL-1ForwardGCTCCAAAGGACTTGTACGTGPDL-1ForwardTGGCATTTGCTGAACGCATTTReversedGCTCCAAAGGACTTGTACGTGReversedTGCAGCCAGGTCTAATTGTTTTE-cadherinForwardGGTCATCAGTGTGCTCACCTCTE-cadherinForwardGCCTCCTGAAAAGAGAGTGGAAGReversedGCTGTTGTGCTCAAGCCTTCACReversedTGGCAGTGTCTCTCCAAATCCGVimentinForwardCGGAAAGTGGAATCCTTGCAGGVimentinForwardAGGCAAAGCAGGAGTCCACTGAReversedAGCAGTGAGGTCAGGCTTGGAAReversedATCTGGCGTTCCAGGGACTCATTGF-βForwardTGATACGCCTGAGTGGCTGTCTTGF-βForwardGAGCTCCGAGAAGCGGTACCTReversedCACAAGAGCAGTGAGCGCTGAAReversedAGGCTCCAAATGTAGGGGCAGG DNA oligonucleotides and quantitative PCR primer sequence For Western blot analysis, RM-1 and DU145 cells treated with Aidi injection were collected, rinsed twice with ice-cold PBS, and lysed in RIPA buffer with 1% APMSF protease inhibitor (LanMu, China) at 4℃ for 30 min. Protein concentrations were measured using the BCA Protein Assay Kit (Solaibio, China). Equal amounts of protein (80 µg) were loaded onto 8–15% SDS-PAGE gels, separated, and transferred to polyvinylidene fluoride (PVDF) membranes. Membranes were blocked with 5% non-fat milk solution and incubated overnight with primary antibodies (Including the following primary antibodies: Bcl-xl, PCNA, Bax, BIRC5, P-STAT3 (Thy705), IL-6, STAT3, AKT1/2, P-AKT1 (Ser479)) at 4℃, followed by washing with TBST and incubation with secondary antibodies. Chemiluminescence detection was performed using the SuperPico ECL Chemiluminescence Kit (E422-01, Vazyme). The blots were imaged using the Tanon 4800 imaging system. β-actin was used as a loading control. Immunofluorescence Cells were seeded in a 12-well plate and treated with varying concentrations of Aidi injection for 24 h. After treatment, cells were fixed, permeabilized, and blocked with 5% BSA in PBS for 1 h at room temperature. Primary antibody incubation was done in 1% BSA in PBS overnight at 4℃. After rinsing, cells were incubated with the secondary antibody in 1% BSA in PBS for 1 h at room temperature in the dark. Cells were subsequently washed, stained with DAPI, and images were captured using a fluorescence microscope. Protein Preparation and Binding Affinity Analysis To produce the STAT3 (127-668aa) protein, an E. coli Rosetta strain was transformed with a recombinant pET-32a(+) plasmid containing the STAT3 sequence encoding amino acids 127 to 688, excluding the ND and TAD regions. The crude protein extract underwent ion-exchange chromatography for purification, and the purified STAT3 (127-668aa) protein was stored in elution buffer (50 mM Tris, pH 8.5, 150 mM NaCl, 1 mM DTT). A construct covering amino acids 696–1022 of human EGFR was prepared as described previously and subcloned into a GST-fusion format using the pTriEX system (Novagen) for expression in Sf9 insect cells [14]. EGFR kinase proteins were purified by glutathione-affinity chromatography, followed by size-exclusion chromatography, with the GST tag removed by TEV or thrombin cleavage according to established protocols [15]. MicroScale Thermophoresis (MST) was used to quantify molecular interactions based on movement along a temperature gradient and other temperature-dependent factors influenced by ligand binding. Purified proteins were labeled with red fluorescent dye NT-647-NHS using a Monolith NTTM Protein Labeling Kit (NanoTemper Technologies). Serial dilutions of test compounds (0 to 1 mM) were mixed with 10 mM NT-647-labeled protein, incubated for 30 min at room temperature in buffer, and loaded into glass capillaries. MST curves were analyzed using NT Analysis software (NanoTemper Technologies) to determine precise Kd binding affinity values. In Vivo Tumorigenic Assay and Immunohistochemistry The antitumor effects of Aidi injection were evaluated using the RM-1 mouse prostate cancer model. All animal procedures were conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines of Guangzhou University of Chinese Medicine (License No.: SYXK (Yue) 2022 − 0179, Approval No.: 2023052409), with approval granted on May 24, 2023. Five-week-old male C57BL/6 mice (20 ± 2 g, obtained from the Animal Center of Guangzhou University of Chinese Medicine) were housed in a temperature-controlled environment with a 12-hour light/dark cycle. RM-1 prostate cancer cell blocks (2 × 10⁶ cells per mouse in 50 µL PBS mixed with an equal volume of Matrigel) were subcutaneously implanted into the backs of the mice. After tumor formation, mice were randomly assigned to four groups: 0.9% NaCl (negative control), 15 mL/kg Aidi injection, 30 mL/kg Aidi injection, and Taxol (20 mg/kg, positive control), with eight mice per group. Randomization was performed using a computer-generated randomization method, and blinding was maintained during data collection and analysis. Two weeks after tumor implantation, Aidi injection (15 or 30 mL/kg) was administered intraperitoneally every other day for a total of 11 doses. Mice in the control group received 0.9% NaCl, and those in the positive control group were treated with Taxol. Tumor size and body weight were monitored every two days, with tumor volume calculated using the formula: V (mm³) = width (mm) × length (mm)²/2. Health monitoring was conducted daily, including body weight, activity, and food intake. If any mouse lost more than 20% of its body weight or showed signs of severe distress, humane euthanasia was performed. After the final injection, mice were euthanized using CO₂ asphyxiation, and tumors were excised, weighed, and fixed in 4% paraformaldehyde for 24 hours at room temperature, followed by paraffin embedding. Immunohistochemical staining was performed on paraffin-embedded tumor tissues using antibodies against PCNA (1:4000) and BIRC5 (1:200), and the reaction products were visualized using a 3,3’-diaminobenzidine (DAB) substrate kit (Solarbio, Beijing, China) according to the manufacturer’s protocol. Statistical Analysis All experiments were repeated a minimum of three times to ensure reliability. Data from cell experiments are expressed as mean ± SEM. Statistical analysis was conducted using SPSS version 19.0. Group differences were assessed with one-way ANOVA, followed by Student’s t-test for pairwise comparisons. Specifying statistical tests and software version improves the reproducibility and transparency of the analysis. A *P-value < 0.05 was considered statistically significant. Results Screening of Active Compounds and Potential Targets in Aidi Injection To identify active compounds in Aidi injection, two key ADME parameters were used: oral bioavailability (OB) ≥ 30% and drug likeness (DL) ≥ 0.18. Using the TCMSP and TCM-ID databases, we identified 58 potential compounds from four traditional Chinese medicinal herbs (Fig. 1A and Supplemental Table 1). Among these, Cantharidin, a natural toxin from beetles in the Meloidae and Oedemeridae families, is known for its strong cytotoxic and inhibitory effects on various cancer cell types, including gastric, lung, esophageal, prostate, cervical, and laryngeal cancers. In our study, Cantharidin (OB = 51.23, DL = 0.1) was one of the identified compounds. Fig. 1The potential targets of Aidi injection and the overlapping therapeutic target genes in prostate cancer were visualized using a Venn diagram. (A) Aidi injection, a type of Chinese patent medicine, consists of four individual traditional Chinese medicine components. (B) A total of 804 putative targets of Aidi injection were identified from the DrugBank and SwissTargetPrediction databases. (C) A total of 490 overlapping therapeutic targets were retrieved from the DisGeNET, GeneCards, and GeneCLip databases. (D) 126 genes overlapped between Aidi injection and prostate cancer The potential targets of Aidi injection and the overlapping therapeutic target genes in prostate cancer were visualized using a Venn diagram. (A) Aidi injection, a type of Chinese patent medicine, consists of four individual traditional Chinese medicine components. (B) A total of 804 putative targets of Aidi injection were identified from the DrugBank and SwissTargetPrediction databases. (C) A total of 490 overlapping therapeutic targets were retrieved from the DisGeNET, GeneCards, and GeneCLip databases. (D) 126 genes overlapped between Aidi injection and prostate cancer Next, we entered the molecular names and SMILES codes of these active compounds into the DrugBank and SwissTargetPrediction databases, identifying a total of 804 potential targets, including PTGS2, IL-6, STAT3, ESR1, HSPAA1, EGFR, among others (Fig. 1B). Identification of Known Therapeutic Targets for Prostate Cancer The study systematically searched for prostate cancer-related genes across three databases—DisGeNET, GeneCards, and GenCLiP 3—using “prostate cancer” as the search term. This search yielded 683 targets from DisGeNET, 9,758 from GeneCards, and 2,720 from GenCLiP 3. After removing duplicates, 490 unique therapeutic targets were identified (Fig. 1C). By comparing these with the targets associated with Aidi injection, 126 overlapping therapeutic targets were found, which are displayed in a Venn diagram (Fig. 1D). Drugs-Compounds-Targets Network Analysis To delve deeper into the therapeutic targets of Aidi injection for prostate cancer, we examined the GSE46602 dataset, identifying 4,955 differentially expressed genes (DEGs). By cross-referencing these DEGs with selected therapeutic targets, we narrowed down 49 key in vivo targets for prostate cancer treatment (Fig. 2A, B). We then used Cytoscape 3.7.1 to map out a network showing connections among herbs, compounds, and targets: diamond nodes represent four traditional Chinese medicinal herbs, circular nodes represent 58 active compounds, and square nodes represent the 49 shared targets, with edges illustrating their interactions. Analysis of network topology highlighted centralization and heterogeneity values of 0.232 and 0.906, respectively, underscoring the prominence of certain compounds and targets. Notably, compounds like Quercetin (degree = 64), Kaempferol (degree = 40), 7-O-methylisomucronulatol (degree = 24), Gomisin B (degree = 24), Jaranol (degree = 22), and Isorhamnetin (degree = 22) emerged as potential key players in prostate cancer treatment (Fig. 2C). To investigate the interactions among the 49 shared targets, we developed a protein-protein interaction (PPI) network to highlight targets with significant regulatory roles. We uploaded these targets to the STRING database and visualized the network using Cytoscape 3.7.1. This resulted in a PPI network comprising 49 protein nodes connected by 292 interactions, with an average node degree of 11.9 and an average local clustering coefficient of 0.667. Further analysis identified ESR1 (degree = 36), HSP90AA1 (degree = 32), STAT3 (degree = 29), EGFR (degree = 29), and VEGFA (degree = 28) as pivotal targets, all of which are closely linked to inflammatory and invasive processes (Fig. 2D). Fig. 2The network of effective ingredients and target genes involved in the therapeutic mechanism of Aidi injection for treating prostate cancer. (A) The volcano plot illustrates significantly expressed genes, with red dots indicating up-regulated genes and green dots indicating down-regulated genes. (B) By overlapping the 126 screened therapeutic targets with differentially expressed genes, we identified 49 key therapeutic targets. (C) The drug-active ingredient-target network diagram illustrates the complex relationships among Chinese herbal medicines (represented by diamond-shaped nodes), including LV for Mylabris phalerata, PGSM for Panax ginseng, ASH for Eleutherococcus senticosus, and ATPX for Astragalus mongholicus, their effective active ingredients (represented by circular nodes) surrounding their respective herbal medicines, and the overlapping targets (represented by square nodes). (D) The common target protein-protein interaction (PPI) network displays interactions among target genes, where node size reflects their importance The network of effective ingredients and target genes involved in the therapeutic mechanism of Aidi injection for treating prostate cancer. (A) The volcano plot illustrates significantly expressed genes, with red dots indicating up-regulated genes and green dots indicating down-regulated genes. (B) By overlapping the 126 screened therapeutic targets with differentially expressed genes, we identified 49 key therapeutic targets. (C) The drug-active ingredient-target network diagram illustrates the complex relationships among Chinese herbal medicines (represented by diamond-shaped nodes), including LV for Mylabris phalerata, PGSM for Panax ginseng, ASH for Eleutherococcus senticosus, and ATPX for Astragalus mongholicus, their effective active ingredients (represented by circular nodes) surrounding their respective herbal medicines, and the overlapping targets (represented by square nodes). (D) The common target protein-protein interaction (PPI) network displays interactions among target genes, where node size reflects their importance Gene Ontology and Pathway Enrichment Analysis To better understand the biological functions of key hub genes, we conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. GO analysis covered three main categories, and the top ten enriched terms for each were visualized using an online platform (http://www.bioinformatics.com.cn/?p=14) (Fig. 3A). The findings are summarized as follows: In the Biological Process (BP) category, the main terms involved regulation of cellular processes (49 targets), organic substance metabolism (46 targets), and biological regulation (46 targets). In the Molecular Function (MF) category, targets were enriched for binding activities (48 targets), protein binding (38 targets), and catalytic activity (37 targets). For the Cellular Component (CC) category, targets were primarily associated with membrane-bounded organelles (45 targets), intracellular organelles (42 targets), and intracellular membrane-bounded organelles (41 targets). These GO enrichment results suggest that the active compounds in Aidi injection participate in a wide range of cellular processes relevant to prostate cancer treatment. Fig. 3GO terms and pathway enrichment analysis. (A) Representative histograms of the top eight entries of BP, CC, and MF. The X-axis indicates the GO terms, and the Y-axis indicates the number of genes included in that specific GO term. (B) Reactome pathways analysis results of the 49 hub genes. This figure provides a genome-wide summary of the reactome pathway analysis. The root of each circular “burst” is the top-level pathway. The distance from the center represents the next lower level in the pathway hierarchy. The color code indicates the over-representation of each pathway, while light grey designates pathways that are not significantly over-represented GO terms and pathway enrichment analysis. (A) Representative histograms of the top eight entries of BP, CC, and MF. The X-axis indicates the GO terms, and the Y-axis indicates the number of genes included in that specific GO term. (B) Reactome pathways analysis results of the 49 hub genes. This figure provides a genome-wide summary of the reactome pathway analysis. The root of each circular “burst” is the top-level pathway. The distance from the center represents the next lower level in the pathway hierarchy. The color code indicates the over-representation of each pathway, while light grey designates pathways that are not significantly over-represented We further analyzed the 49 screened DEGs for genome-wide pathway associations using the Reactome database, identifying 586 pathways with P-values ≤ 0.05 (Fig. 3B). Key pathway clusters with more than ten enriched pathways were concentrated in five categories: Immune System (24/2,641, FDR: 9.93e-2), Signal Transduction (36/3,158, FDR: 3.11e-3), Gene Expression (33/1,751, FDR: 6.23e-7), Programmed Cell Death (6/188, FDR: 1.34e-2), and Cellular Responses to External Stimuli (11/829, FDR: 1.47e-5). These findings suggest that Aidi injection’s active compounds may exert therapeutic effects in prostate cancer by enhancing immune responses and promoting cell death pathways. Molecular Docking To validate the findings from network pharmacology, molecular docking was conducted to examine interactions between selected active compounds and core targets. The docking focused on top targets such as ESR1, HSP90AA1, IL6, STAT3, EGFR, and VEGFA; the six highest-degree compounds in the herb-compound-target network; and Cantharidin. Binding energy values were used to evaluate docking results, with values above 7 kcal/mol indicating strong binding potential. The spatial coordinates for docking, along with details of targets and compounds, are provided in Table 3; Fig. 4. Table 3The binding affinity of the core active ingredients of the Aidi injection with the key proteinActive ingredientsBinding energy (kcal/mol)ESR1HSP90AA1IL-6STAT3EGFRQuercetin−7.19−7.48−4.26−5.97−8.62Kaempferol−7.43−7.63−4.66−5.5−8.67-O-methylisomucronulatol−6.71−6.77−4.06−4.66−7.32Gomisin B−4.89−7.48−3.61−2.73−5.37Jaranol−7.82−7.43−4.09−5.71−7.09Isorhamnetin−7.55−6.7−4.35−5.11−7.97Cantharidin−6.4−7.63−4.84−5.16−8.5 Table 3The binding affinity of the core active ingredients of the Aidi injection with the key proteinActive ingredientsBinding energy (kcal/mol)ESR1HSP90AA1IL-6STAT3EGFRQuercetin−7.19−7.48−4.26−5.97−8.62Kaempferol−7.43−7.63−4.66−5.5−8.67-O-methylisomucronulatol−6.71−6.77−4.06−4.66−7.32Gomisin B−4.89−7.48−3.61−2.73−5.37Jaranol−7.82−7.43−4.09−5.71−7.09Isorhamnetin−7.55−6.7−4.35−5.11−7.97Cantharidin−6.4−7.63−4.84−5.16−8.5 The binding affinity of the core active ingredients of the Aidi injection with the key protein Fig. 4Docking patterns of key targets (EGFR and STAT3) and top-ranked six active ingredients Docking patterns of key targets (EGFR and STAT3) and top-ranked six active ingredients The results revealed that EGFR exhibited strong binding affinity with the six selected compounds, especially Quercetin and Kaempferol, which had the highest binding energies of −8.62 kcal/mol and − 8.6 kcal/mol, respectively. Quercetin formed hydrogen bonds with EGFR residues ASP800, ASP855, and THR790, while also engaging in conjugated interactions with LEU718, VAL726, and CYS797. Kaempferol, on the other hand, formed hydrogen bonds with ASP855 and THR854, and exhibited conjugated interactions with GLY857 and LEU777. Additionally, Quercetin interacted with STAT3 through hydrogen bonds with GLY519, GLN524, TRP580, LEU608, and TYR974, and conjugated interactions with TYR764. Furthermore, stable complexes were formed between Kaempferol, Jaranol, Isorhamnetin, and key targets such as ESR1, HSP90AA1, and STAT3, highlighting their strong binding potential (Supplemental Fig. 1). These findings suggest that these compounds may serve as promising drug candidates for further experimental validation due to their effective binding to target proteins via hydrogen bonding and hydrophobic interactions. Effects of Aidi Injection on the Proliferation and Viability of RM-1, DU145 and BPH-1 Cells in Vitro The impact of Aidi injection on prostate cancer cells was assessed using the CCK-8 assay. Treatment with increasing doses of Aidi injection (0-200 mg/ml) over 24–48 h led to a dose- and time-dependent decrease in cell viability in all cell types (Fig. 5A). RM-1 (a mouse prostate cancer cell line) and DU145 (a human prostate cancer cell line) were chosen for this study to represent both species-specific models of prostate cancer. BPH-1 cells were excluded due to their lack of sensitivity to Aidi injection. DU145 cells showed greater sensitivity to Aidi injection compared to RM-1 cells at each time point, with IC50 values of 94.3 ± 3.56 mg/ml and 56.8 ± 2.21 mg/ml, respectively (Fig. 5A). Following Aidi injection exposure, the clonogenic ability of prostate cancer cells was significantly reduced, with a marked decrease in colony numbers compared to the control, indicating that Aidi injection effectively inhibits prostate cancer cell proliferation (Fig. 5B). Furthermore, cell proliferation assays showed a notable decrease in proliferation rates, and by day six, cell growth was fully suppressed, aligning with the clonogenic assay results (Fig. 5C). Fig. 5Effects of Aidi injection on cell viability in RM-1, DU145, BPH-1 and RWPE-1 cells. (A) Cell viability was dose-dependently suppressed following treatment with Aidi injection at indicated concentrations for 24–48 h. (B-C) Aidi injection significantly inhibited the proliferation of RM-1 and DU145 cells, as evidenced by clonogenic assay results showing a reduction in the number of colonies formed. (D) Western blot analysis of RM-1 and DU145 cells treated with Aidi injection for 24 h, revealing decreased expression levels of PCNA. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Effects of Aidi injection on cell viability in RM-1, DU145, BPH-1 and RWPE-1 cells. (A) Cell viability was dose-dependently suppressed following treatment with Aidi injection at indicated concentrations for 24–48 h. (B-C) Aidi injection significantly inhibited the proliferation of RM-1 and DU145 cells, as evidenced by clonogenic assay results showing a reduction in the number of colonies formed. (D) Western blot analysis of RM-1 and DU145 cells treated with Aidi injection for 24 h, revealing decreased expression levels of PCNA. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Western blot analysis revealed significant down-regulation of PCNA protein levels, particularly in the high-dose treatment group, indicating that Aidi injection effectively suppresses prostate cancer cell proliferation at the molecular level (Fig. 5D). Aidi Injection Can Significantly Reduce the Migration Ability of Prostate Cancer Cells To assess the impact of Aidi injection on the migration and invasion abilities of prostate cancer cells, we analyzed gene expression changes following treatment. Wound healing assays revealed that Aidi injection markedly decreased prostate cancer cell migration (Fig. 6A, B). Key migration and invasion markers, including E-cadherin, Vimentin, and TGFB1 genes, were further examined. The results showed a dose-dependent increase in E-cadherin levels, while Vimentin and TGFB1 expressions significantly decreased after treatment (Fig. 6C). Immunofluorescence staining also indicated a notable reduction in Vimentin expression in RM-1 and DU145 cells (Fig. 6D). These findings suggest that Aidi injection effectively diminishes the migratory and invasive properties of prostate cancer cells, offering potential therapeutic benefits in slowing disease progression. Fig. 6Aidi injection inhibits the invasive capabilities of prostate cancer cells. (A-B) RM-1 and DU145 cells were treated with varying concentrations of Aidi injection, and the extent of cell migration was measured at different time points. (C) qRT-PCR was used to assess the relative expression levels of key genes involved in cell migration (E-cadherin, Vimentin, and TGFB1) after treatment with Aidi injection. (D) Results from immunofluorescence (IF) staining following Aidi injection treatment are presented (magnification ×200, scale bar: 100 μm). All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Aidi injection inhibits the invasive capabilities of prostate cancer cells. (A-B) RM-1 and DU145 cells were treated with varying concentrations of Aidi injection, and the extent of cell migration was measured at different time points. (C) qRT-PCR was used to assess the relative expression levels of key genes involved in cell migration (E-cadherin, Vimentin, and TGFB1) after treatment with Aidi injection. (D) Results from immunofluorescence (IF) staining following Aidi injection treatment are presented (magnification ×200, scale bar: 100 μm). All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Aidi Injection Induces Apoptosis in Prostate Cancer Cells with Notable Chromosome Condensation To investigate Aidi injection’s ability to induce apoptosis in prostate cancer cells, we used staining techniques and flow cytometry to observe cellular changes. JC-1 staining showed a dose-dependent decrease in mitochondrial membrane potential across various Aidi injection concentrations (Fig. 7A). Nuclear chromatin changes were examined using DAPI staining, which revealed significant nuclear shrinkage and chromatin condensation in prostate cancer cells treated with 25, 50, or 100 mg/mL of Aidi injection (Fig. 7B). Flow cytometry confirmed a significant increase in apoptosis at concentrations above 25 mg/mL, with DU145 cells showing greater sensitivity to apoptosis than RM-1 cells (Fig. 7C). Additionally, western blot analysis revealed an elevated Bax/Bcl-xl ratio and a marked reduction in the survival protein BIRC5 (Fig. 7D), further confirming the apoptosis-inducing effects of Aidi injection. Fig. 7Aidi injection induced programmed cell death in RM-1 and DU145 cells. (A) JC-1 staining results revealed that Aidi injection significantly lowers mitochondrial membrane potential (magnification ×400, scale bar: 200 μm). (B-C) RM-1 and DU145 cells were treated with various concentrations of Aidi injection (0, 25, 50, 100 mg/ml) for 24 h, followed by DAPI staining and analysis using flow cytometry. These experiments demonstrated that Aidi injection effectively induced programmed cell death in prostate cancer cells, with DU145 cells showing higher sensitivity to the treatment (magnification ×400, scale bar: 200 μm). (D) Western blot analysis of RM-1 and DU145 cells after 24 h of treatment with Aidi injection revealed alterations in the expression levels of apoptosis-related proteins Bcl-xl, Bax, and BIRC5, further supporting the induction of programmed cell death. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Aidi injection induced programmed cell death in RM-1 and DU145 cells. (A) JC-1 staining results revealed that Aidi injection significantly lowers mitochondrial membrane potential (magnification ×400, scale bar: 200 μm). (B-C) RM-1 and DU145 cells were treated with various concentrations of Aidi injection (0, 25, 50, 100 mg/ml) for 24 h, followed by DAPI staining and analysis using flow cytometry. These experiments demonstrated that Aidi injection effectively induced programmed cell death in prostate cancer cells, with DU145 cells showing higher sensitivity to the treatment (magnification ×400, scale bar: 200 μm). (D) Western blot analysis of RM-1 and DU145 cells after 24 h of treatment with Aidi injection revealed alterations in the expression levels of apoptosis-related proteins Bcl-xl, Bax, and BIRC5, further supporting the induction of programmed cell death. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Aidi Injection Modulates Programmed Cell Death Via the IL-6/STAT3 Signaling Pathway Using network pharmacology predictions, we identified that Aidi injection addresses prostate cancer by enhancing immune responses and promoting programmed cell death, particularly through modulation of the IL-6/STAT3 signaling pathway, which plays a critical role in apoptosis. Experimental validation showed that Aidi injection treatment significantly reduced IL-6 and PDL-1 expression levels, while effectively upregulating CXCL-10 and IFN-γ, as detected by qRT-PCR. This response led to T cell cross-sensitization and immune cell recruitment to the tumor, enhancing T cell cytotoxicity against tumor cells and reducing PDL-1 expression (Fig. 8A). Western blot analysis confirmed a marked decrease in IL-6 expression in both prostate cancer cell lines after Aidi injection treatment. Although the total STAT3 and AKT protein levels remained stable, their phosphorylation levels decreased in a dose-dependent manner (Fig. 8B). Further experiments demonstrated that LPS stimulation increased IL-6 and P-STAT3 levels, promoting cell survival, while Aidi injection significantly suppressed the IL-6/STAT3 pathway, reducing LPS-induced cell survival, indicating the drug’s targeted effect on this pathway to induce apoptosis (Fig. 9A, B). Additionally, STAT3 activation and dimerization in DU145 cells were examined, showing that Aidi injection significantly enhanced STAT3 dimerization and phosphorylation (Fig. 9C). Fig. 8Aidi injection modulates immune-related markers and the IL-6/STAT3 signaling pathway in prostate cancer cells. (A) qRT-PCR results showing its effect on the mRNA expression levels of IL6, CXCL-10, IFNγ, and PD-L1; (B) Western blot analysis indicating its modulation of IL-6, p-STAT3, and p-AKT protein expression levels in RM-1 and DU145 cells. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Aidi injection modulates immune-related markers and the IL-6/STAT3 signaling pathway in prostate cancer cells. (A) qRT-PCR results showing its effect on the mRNA expression levels of IL6, CXCL-10, IFNγ, and PD-L1; (B) Western blot analysis indicating its modulation of IL-6, p-STAT3, and p-AKT protein expression levels in RM-1 and DU145 cells. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Fig. 9Aidi injection promotes programmed cell death by inhibiting the IL6/STAT3 signaling pathway. (A) Western blot analysis demonstrating the inhibitory effect of Aidi injection on the IL-6/STAT3/AKT signaling pathway. The expression of IL-6, P-STAT3, and P-AKT was significantly suppressed. Moreover, Aidi injection effectively reverses LPS-induced activation of the IL-6/STAT3 pathway, promoting cell death. (B) Flow cytometry analysis showed that Aidi injection effectively reverses LPS-induced reduction in cell viability. (C) After treatment with Aidi injection, there was a promotion in the activation of p-STAT3 and the dimerization of STAT3 (magnification ×400, scale bar: 200 μm). (D) Molecular docking analysis revealed high binding affinity of Quercetin, Kaempferol, Isorhamnetin, and Cantharidin to EGFR and STAT3. MST analysis confirmed precise Kd values, validating their potential as therapeutic agents. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Aidi injection promotes programmed cell death by inhibiting the IL6/STAT3 signaling pathway. (A) Western blot analysis demonstrating the inhibitory effect of Aidi injection on the IL-6/STAT3/AKT signaling pathway. The expression of IL-6, P-STAT3, and P-AKT was significantly suppressed. Moreover, Aidi injection effectively reverses LPS-induced activation of the IL-6/STAT3 pathway, promoting cell death. (B) Flow cytometry analysis showed that Aidi injection effectively reverses LPS-induced reduction in cell viability. (C) After treatment with Aidi injection, there was a promotion in the activation of p-STAT3 and the dimerization of STAT3 (magnification ×400, scale bar: 200 μm). (D) Molecular docking analysis revealed high binding affinity of Quercetin, Kaempferol, Isorhamnetin, and Cantharidin to EGFR and STAT3. MST analysis confirmed precise Kd values, validating their potential as therapeutic agents. All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Finally, based on the resolved structures of EGFR and STAT3, protein purification was conducted, followed by MST analysis to evaluate protein-small molecule binding affinities (Kd values). Results revealed that Quercetin and Cantharidin had strong binding with EGFR, while Quercetin, Isorhamnetin, and Kaempferol showed enhanced binding with STAT3 (Fig. 9D). These findings further confirm that Aidi injection promotes apoptosis by targeting the IL-6/STAT3 signaling pathway, boosting immune function, enhancing T cell cytotoxicity, reducing inflammation, and effectively treating prostate cancer. Aidi Injection Exhibits Potent Antitumor Activity in Homograft Mice Bearing RM-1 Tumors Based on comprehensive findings, further exploration of Aidi injection’s antitumor efficacy in vivo is justified. Mice were treated every two days with 15 or 30 ml/kg of Aidi injection, totaling eleven doses, with taxol as a positive control (Fig. 10A). Notably, tumor growth was significantly inhibited in the Aidi-treated group compared to controls after 22 days (Fig. 10B). Body weight, an indicator of overall health, remained stable between treatment and control groups, showing a slight increase over time (Fig. 10C). Tumor weight was also significantly lower in the Aidi-treated group compared to the control (Fig. 10D). Fig. 10Aidi injection attenuated tumor growth by inhibiting cell proliferation and enhancing immunity in RM-1 homograft mice. (A) Schematic representation of the administration schedule and dosing regimen for C57BL/6 mice bearing RM-1 homografts. (B-D) Monitoring of body weight changes and tumor volume alterations in control and treatment groups post-administration, along with tumor weight measurements. (E) Assessment of changes in inflammatory cytokine IL-6 and chemokine CXCL-10 levels in mouse serum post-administration. (F) Evaluation of proliferation and distribution of CD8+ CXCR3+ and CD4+ Treg Foxp3 cells in tumor tissues and spleens post-treatment. (G) Immunohistochemistry staining results demonstrating decreased expression of BIRC5 and PCNA in the treatment group, indicating significant suppression of tumor tissue proliferation and promotion of tumor cell death (magnification ×400, scale bar: 200 μm). All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Aidi injection attenuated tumor growth by inhibiting cell proliferation and enhancing immunity in RM-1 homograft mice. (A) Schematic representation of the administration schedule and dosing regimen for C57BL/6 mice bearing RM-1 homografts. (B-D) Monitoring of body weight changes and tumor volume alterations in control and treatment groups post-administration, along with tumor weight measurements. (E) Assessment of changes in inflammatory cytokine IL-6 and chemokine CXCL-10 levels in mouse serum post-administration. (F) Evaluation of proliferation and distribution of CD8+ CXCR3+ and CD4+ Treg Foxp3 cells in tumor tissues and spleens post-treatment. (G) Immunohistochemistry staining results demonstrating decreased expression of BIRC5 and PCNA in the treatment group, indicating significant suppression of tumor tissue proliferation and promotion of tumor cell death (magnification ×400, scale bar: 200 μm). All data presented are representative of three independent experiments and are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group Serum analysis post-treatment showed a substantial decrease in IL-6 levels and an increase in CXCL-10 levels (Fig. 10E). Flow cytometry of tumor and spleen tissues revealed a significant rise in CD8+ CXCR3+ cells and increased Foxp3 expression in CD4+ Treg cells, indicating immune activation, enhanced immune cell proliferation and migration, and improved tumor immune infiltration and cell killing (Fig. 10F). Additionally, immunohistochemistry showed a marked reduction in the proliferation markers PCNA and BIRC5 in the Aidi injection-treated group, aligning with in vitro findings (Fig. 10G). Discussion Prostate cancer, the most prevalent malignancy of the male reproductive system, is described in traditional Chinese medicine (TCM) with various pathological types, including “blood stasis,” “damp-heat accumulation,” and “kidney deficiency with dampness.” According to TCM theory, prostate cancer arises primarily from factors such as kidney meridian imbalance, qi stagnation, internal damp-heat, and blood stasis [16]. Aidi injection, with blister beetle as the principal herb, supplemented by astragalus, ginseng, and eleuthero, collectively possesses the functions of clearing heat, detoxifying, and anti-cancer effects, while also tonifying qi, promoting blood circulation, and resolving stasis [17]. Studies by Gu Jianyi et al. have shown that Aidi injection, when combined with complete androgen blockade therapy for advanced prostate cancer, significantly reduces serum PSA, FPSA, and T levels compared to baseline. The treatment group also demonstrated higher levels of CD3+ and CD4+ cells and an improved CD4+/CD8+ ratio, along with enhanced IPSS scores, quality of life, and survival-related quality measures [18]. This study utilized network pharmacology to discover that Aidi injection contains 58 effective components targeting 804 different targets. Among them, Quercetin, Kaempferol, Isorhamnetin and Cantharidin are considered key therapeutic components for treating prostate cancer using Aidi injection. Cantharidin, categorized as highly toxic in traditional Chinese medicine, demonstrates efficacy in treating solid tumors, refractory skin diseases, and other conditions [19]. Studies show that Cantharidin can regulate the miR-607/EGFR pathway, influencing breast cancer cell survival and growth [20]. Additionally, Quercetin and Isorhamnetin—active compounds found in Astragalus mongholicus and Eleutherococcus senticosus—have been shown to significantly inhibit colon cancer cell proliferation [21]. The research by Huijuan Liu et al. shows that Isorhamnetin (ISO) specifically targets USP7, promoting YY1 ubiquitin-dependent degradation, which inhibits YY1 stability and suppresses HCC cell proliferation, migration, and EMT. Meanwhile, HMSN-ISO@ProA-PD-L1 Ab nanoparticles further enhance tumor growth inhibition and immune modulation [22]. The results of PPI topology analysis suggest that ESR1, IL-6, STAT3, HSP90AA1, EGFR, and VEGFA are likely core targets of Aidi injection in treating prostate cancer, with high degree values. Research indicates that abnormal activation of the STAT3 signaling pathway can inhibit immune cell activity, decreasing their attack on tumor cells and allowing tumors to evade immune surveillance [23–25]. Additionally, the STAT3 signaling pathway promotes various characteristics of tumor initiation and metastasis, such as enhanced cell proliferation, survival, and migration into the extracellular matrix [26]. Complex interactions and regulatory relationships exist between EGFR and VEGFA, where EGFR signaling pathway activation induces VEGFA expression, promoting angiogenesis and tumor vascularization, thus influencing the growth and invasiveness of tumor cells [27, 28]. According to KEGG pathway enrichment analysis, pathways such as Immune System, Signal Transduction, Programmed Cell Death, and Cellular Responses to External Stimuli are the primary pathways involved in Aidi injection’s therapeutic effect on prostate cancer. Among these, the IL-6/STAT3 signaling pathway plays a pivotal role in prostate cancer treatment, as it is aberrantly activated in various cancers and is often associated with poor clinical outcomes. Within the tumor microenvironment, the IL-6/STAT3 pathway promotes tumor cell proliferation, survival, invasion, and metastasis while strongly suppressing anti-tumor immune responses. Studies have shown that gut microbiota dysbiosis can activate the NF-κB pathway, leading to IL-6 release, which in turn activates the STAT3 pathway, promoting prostate cancer progression and resistance to docetaxel [29]. Our findings indicate that Aidi injection effectively inhibits the IL-6/STAT3 signaling pathway activation, reducing inflammatory infiltration in prostate cancer, improving patient quality of life and treatment outcomes, and enhancing immune cell-mediated tumor killing by increasing the CD4+/CD8+ ratio. Molecular docking results show that the seven key components of Aidi injection exhibit good binding affinity with five core proteins, with Quercetin and Kaempferol showing particularly high binding affinity with these core proteins. Further, our in vitro experiments confirmed that Aidi injection significantly suppresses the proliferative ability of multiple prostate cancer cell lines, as demonstrated by the marked reduction in the proliferation marker PCNA following treatment. Results from flow cytometry and JC-1 staining showed that Aidi injection induces apoptosis in prostate cancer cells. Western blot analysis indicated a notable increase in the Bax/Bcl-xl ratio, suggesting that higher drug concentrations effectively trigger programmed cell death in these cells. Additionally, our qRT-PCR results demonstrated a noticeable increase in CXCL-10 and IFNγ levels post-treatment with the drug, suggesting enhanced immune cell cross-sensitization and infiltration into tumor tissues. Decreased PDL-1 expression was observed, indicating increased cytotoxicity of T cells against tumor cells. Furthermore, we investigated the impact of Aidi injection on the IL-6/STAT3 pathway and found that it significantly inhibited the expression of IL-6 and p-STAT3/p-AKT. Treatment with Aidi injection notably attenuated the IL-6/STAT3 signaling pathway, thereby diminishing cell survival induced by LPS, thereby highlighting the drug’s targeted effect on this pathway to promote programmed cell death. Based on the docking results, we selected four compounds for validation of their binding abilities with important target proteins, revealing that Quercetin and Kaempferol exhibit strong binding capabilities with EGFR and STAT3. In homograft mice bearing RM-1 tumors, Aidi injection significantly reduced inflammation in the mice, increased the activation and migration capabilities of CD8+ and CD4+ Treg cells, and attenuated tumor tissue growth without affecting the physiological status of the mice. In conclusion, our study indicates that Aidi injection may offer therapeutic benefits in slowing PCa progression. This effect appears to be mediated through modulation of the IL-6/STAT3 and EGFR signaling pathways, which results in reduced prostate cancer cell proliferation, initiation of programmed cell death, and decreased cancer cell migration and invasion (Fig. 11). Additionally, in vivo experiments show that Aidi injection supports immune cell proliferation and migration, enhancing anti-tumor immune responses and potentially aiding the advancement of immunotherapy for PCa. Altogether, these findings provide valuable theoretical support for the clinical use of Aidi injection in PCa treatment. Fig. 11Aidi injection mechanism diagram depicting its action on prostate cancer cells. Mechanistically, Aidi injection inhibits the IL-6/STAT3 signaling pathway, reducing inflammation and weakening STAT3 dimerization, which in turn prevents its nuclear translocation. This leads to a decrease in the expression of anti-apoptotic genes and modulates the activation of apoptosis pathways, ultimately promoting cell apoptosis. Additionally, Aidi injection suppresses the EGFR signaling pathway, reducing cell migration and invasion. Specifically, it upregulates the expression of E-cadherin and downregulates the expression of Vimentin, thereby inhibiting cell migration Aidi injection mechanism diagram depicting its action on prostate cancer cells. Mechanistically, Aidi injection inhibits the IL-6/STAT3 signaling pathway, reducing inflammation and weakening STAT3 dimerization, which in turn prevents its nuclear translocation. This leads to a decrease in the expression of anti-apoptotic genes and modulates the activation of apoptosis pathways, ultimately promoting cell apoptosis. Additionally, Aidi injection suppresses the EGFR signaling pathway, reducing cell migration and invasion. Specifically, it upregulates the expression of E-cadherin and downregulates the expression of Vimentin, thereby inhibiting cell migration Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. The selected ingredients and their source in traditional Chinese medicine. Supplementary Material 1. The selected ingredients and their source in traditional Chinese medicine. Supplementary Material 2. The 2D display illustrates the molecular binding modes between the top-ranked six active ingredients and their target proteins, including IL6, HSP90AA1, and ESR1. Supplementary Material 2. The 2D display illustrates the molecular binding modes between the top-ranked six active ingredients and their target proteins, including IL6, HSP90AA1, and ESR1.